Exelixis Announces Webcasts of Investor Conference Presentations in February
February 06 2020 - 4:05PM
Business Wire
Presentations to be webcast on
www.exelixis.com
Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M.
Morrissey, Ph.D., the company’s President and Chief Executive
Officer, will be presenting at the following investor conferences
in February:
- BIO CEO & Investor Conference: Exelixis is scheduled to
present at 2:00 PM EST / 11:00 AM PST on Tuesday, February 11, 2020
in New York.
- Guggenheim Healthcare Talks Oncology Day: Exelixis is scheduled
to present at 9:00 AM EST / 6:00 AM PST on Thursday, February 13,
2020 in New York.
To access the webcast links, log onto www.exelixis.com and
proceed to the News & Events / Event Calendar page under the
Investors & Media heading. Please connect to the company’s
website at least 15 minutes prior to the presentation to ensure
adequate time for any software download that may be required to
listen to the webcasts. Replays will also be available at the same
location for 14 days.
About Exelixis
Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially
successful, oncology-focused biotechnology company that strives to
accelerate the discovery, development and commercialization of new
medicines for difficult-to-treat cancers. Following early work in
model system genetics, we established a broad drug discovery and
development platform that has served as the foundation for our
continued efforts to bring new cancer therapies to patients in
need. Our discovery efforts have resulted in four commercially
available products, CABOMETYX® (cabozantinib), COMETRIQ®
(cabozantinib), COTELLIC® (cobimetinib) and MINNEBRO®
(esaxerenone), and we have entered into partnerships with leading
pharmaceutical companies to bring these important medicines to
patients worldwide. Supported by revenues from our marketed
products and collaborations, we are committed to prudently
reinvesting in our business to maximize the potential of our
pipeline. We are supplementing our existing therapeutic assets with
targeted business development activities and internal drug
discovery - all to deliver the next generation of Exelixis
medicines and help patients recover stronger and live longer.
Exelixis is a member of Standard & Poor’s (S&P) MidCap 400
index, which measures the performance of profitable mid-sized
companies. For more information about Exelixis, please visit
www.exelixis.com, follow @ExelixisInc on Twitter or like Exelixis,
Inc. on Facebook.
Exelixis, the Exelixis logo, CABOMETYX,
COMETRIQ and COTELLIC are registered U.S. trademarks. MINNEBRO is a
registered Japanese trademark.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200206005867/en/
Investors Contact: Varant Shirvanian Sr. Investor
Relations Manager Exelixis, Inc. 650-837-7917
vshirvanian@exelixis.com
Media Contact: Hal Mackins For Exelixis, Inc.
415-994-0040 hal@torchcommunications.com
Exelixis (NASDAQ:EXEL)
Historical Stock Chart
From Apr 2024 to May 2024
Exelixis (NASDAQ:EXEL)
Historical Stock Chart
From May 2023 to May 2024